Niobay Metals Inc (NBY) Downgraded by ValuEngine

ValuEngine downgraded shares of Niobay Metals Inc (NYSEAMERICAN:NBY) from a sell rating to a strong sell rating in a research report released on Friday morning.

Niobay Metals (NYSEAMERICAN:NBY) opened at C$4.20 on Friday. Niobay Metals has a 52 week low of C$2.25 and a 52 week high of C$5.00.

WARNING: “Niobay Metals Inc (NBY) Downgraded by ValuEngine” was reported by Markets Daily and is the property of of Markets Daily. If you are accessing this piece on another site, it was stolen and republished in violation of United States and international copyright law. The legal version of this piece can be accessed at

Niobay Metals Company Profile

NovaBay Pharmaceuticals, Inc, formerly NovaCal Pharmaceuticals, Inc, is a biopharmaceutical company, which develops products for the eye care market. The Company focuses on commercializing prescription Avenova for managing hygiene of the eyelids and lashes in the United States. Avenova is an eye care product formulated with a form of hypochlorous acid called Neutrox.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Niobay Metals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Niobay Metals Inc and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply